Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Genzyme Corp | 22 |
| 2 | Children's Hospital of Philadelphia | 2 |
| 3 | Columbia University | 2 |
| 4 | Affinity (Shanghai) Biopharmaceutical Co Ltd | 1 |
| 5 | DSM IP Assets BV | 1 |
| 6 | Danisco US Inc | 1 |
| 7 | Penn State Research Foundation | 1 |
| 8 | Sanofi Aventis Recherche et Developpement | 1 |
| 9 | The University of Tokyo | 1 |
| 10 | Yale University | 1 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 40 |
| 2 | C07K | Peptides | 28 |
| 3 | A61P | Therapeutic activity (drug indications) | 14 |
| 4 | A61B | 10 | |
| 5 | A61L | Sterilising / disinfecting materials | 8 |
| 6 | G01N | Investigating / analysing materials | 8 |
| 7 | A61Q | Cosmetics, personal care | 6 |
| 8 | A23L | Foods and beverages (general) | 5 |
| 9 | C07D | Heterocyclic compounds | 4 |
| 10 | C12N | Microorganisms, enzymes | 4 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| THE TOTAL SYNTHESIS OF GLUCOSEPANE AND RELATED CHEMICAL REACTIONS, COMPOUNDS AND COMPOSITIONS OBTAINED THEREFROM AND METHODS OF TREATMENT | 2017 | YALE UNIVERSITY | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Collagen: Extraction and Characterization | 1 |
| 2 | Pharmaceutical studies and practices | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Vincent M. Monnier | Case Western Reserve University | 7 |
| 2 | David R. Sell | Case Western Reserve University | 6 |
| 3 | Anthony Nash | University College London | 5 |
| 4 | Helen L. Birch | University College London | 5 |
| 5 | Nora H. de Leeuw | University College London | 5 |
| 6 | Saul Genuth | Case Western Reserve University | 4 |
| 7 | Wanjie Sun | George Washington University | 4 |
| 8 | Attia Anwar | University of Warwick | 3 |
| 9 | Christopher Strauch | Case Western Reserve University | 3 |
| 10 | John M. Lachin | George Washington University | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Effects of Collagen Crosslinking on Bone Material Properties in Health and Disease | 2015 | 199 | Connective tissue disorders research |
| Skin Advanced Glycation End Products Glucosepane and Methylglyoxal Hydroimidazolone Are Independently Associated With Long-term Microvascular Complication Progression of Type 1 Diabetes | 2014 | 147 | Diabetes, Cardiovascular Risks, and Lipoproteins |
| Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications | 2013 | 73 | Natural Antidiabetic Agents Studies |
| Assessing glycationâmediated changes in human cortical bone with Raman spectroscopy | 2018 | 63 | Bone health and osteoporosis research |
| The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes | 2012 | 60 | Diabetes, Cardiovascular Risks, and Lipoproteins |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Glucosepan?
Which organization holds the most patents related to Glucosepan?
What are the primary research areas covered by publications on Glucosepan?
What is the patent classification profile for Glucosepan inventions?
Who are the leading research authors investigating Glucosepan?